Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsBusiness Wire • 02/22/24
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)Business Wire • 02/21/24
AMYLYX SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their OptionsPRNewsWire • 02/21/24
AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!PRNewsWire • 02/18/24
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights – AMLXAccesswire • 02/18/24
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information – AMLXAccesswire • 02/18/24
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) InvestorsBusiness Wire • 02/16/24
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024Business Wire • 02/15/24
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) InvestorsBusiness Wire • 02/15/24
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Amylyx Pharmaceuticals, Inc. (AMLX) on Behalf of InvestorsBusiness Wire • 02/15/24
Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific ConferenceBusiness Wire • 02/15/24
Lost Money on Amylyx Pharmaceuticals, Inc.(AMLX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law FirmPRNewsWire • 02/15/24
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Amylyx Pharmaceuticals, Inc. (AMLX) on Behalf of InvestorsBusiness Wire • 02/15/24
Amylyx Pharmaceuticals, Inc. (AMLX) Stockholder Alert: Robbins LLP Reminds Stockholders of Amylyx Pharmaceuticals, Inc. Class ActionBusiness Wire • 02/14/24
The Law Offices of Frank R. Cruz Announces Investigation of Amylyx Pharmaceuticals, Inc. (AMLX) on Behalf of InvestorsBusiness Wire • 02/14/24
AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLXBusiness Wire • 02/14/24
Lost Money on Amylyx Pharmaceuticals, Inc. (AMLX)? Join Class Action Suit Seeking Recovery – Contact Levi & KorsinskyAccesswire • 02/13/24
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc. (AMLX) InvestorsBusiness Wire • 02/13/24
Shareholders that Lost Money on Amylyx Pharmaceuticals, Inc. (AMLX) Should Contact Levi & Korsinsky about Pending Class Action - AMLXAccesswire • 02/13/24
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLXPRNewsWire • 02/13/24
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLXBusiness Wire • 02/12/24
AMLX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitBusiness Wire • 02/12/24
AMLX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Amylyx Class Action LawsuitBusiness Wire • 02/10/24
